Talkspace, Inc.

NasdaqCM:TALK Stock Report

Market Cap: US$522.0m

Talkspace Valuation

Is TALK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TALK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TALK ($3.16) is trading below our estimate of fair value ($15.82)

Significantly Below Fair Value: TALK is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TALK?

Key metric: As TALK is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for TALK. This is calculated by dividing TALK's market cap by their current revenue.
What is TALK's PS Ratio?
PS Ratio2.9x
SalesUS$181.29m
Market CapUS$521.97m

Price to Sales Ratio vs Peers

How does TALK's PS Ratio compare to its peers?

The above table shows the PS ratio for TALK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.2x
AIRS AirSculpt Technologies
1.9x9.2%US$369.0m
VMD Viemed Healthcare
1.6x12.9%US$335.2m
DCGO DocGo
0.6x-21.8%US$410.2m
INNV InnovAge Holding
0.8x10.5%US$647.5m
TALK Talkspace
2.9x18.8%US$522.0m

Price-To-Sales vs Peers: TALK is expensive based on its Price-To-Sales Ratio (2.9x) compared to the peer average (1.2x).

Price to Sales Ratio vs Industry

How does TALK's PS Ratio compare vs other companies in the US Healthcare Industry?

31 CompaniesPrice / SalesEstimated GrowthMarket Cap
MCK McKesson
0.2x8.1%US$78.15b
CVS CVS Health
0.2x4.6%US$70.18b
COR Cencora
0.2x6.4%US$47.23b
CNC Centene
0.2x5.5%US$29.19b
TALK 2.9xIndustry Avg. 1.0xNo. of Companies31PS012345+
31 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: TALK is expensive based on its Price-To-Sales Ratio (2.9x) compared to the US Healthcare industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is TALK's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TALK PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.9x
Fair PS Ratio1.7x

Price-To-Sales vs Fair Ratio: TALK is expensive based on its Price-To-Sales Ratio (2.9x) compared to the estimated Fair Price-To-Sales Ratio (1.7x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TALK forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$3.16
US$4.33
+37.1%
21.8%US$5.00US$3.00n/a3
Nov ’25US$3.14
US$4.00
+27.4%
25.0%US$5.00US$3.00n/a2
Oct ’25US$2.11
US$3.50
+65.9%
42.9%US$5.00US$2.00n/a2
Sep ’25US$2.00
US$3.50
+75.0%
42.9%US$5.00US$2.00n/a2
Aug ’25US$1.88
US$4.00
+112.8%
25.0%US$5.00US$3.00n/a2
Jul ’25US$2.10
US$4.00
+90.5%
25.0%US$5.00US$3.00n/a2
Jun ’25US$2.62
US$4.00
+52.7%
25.0%US$5.00US$3.00n/a2
May ’25US$3.16
US$4.00
+26.6%
25.0%US$5.00US$3.00n/a2
Apr ’25US$3.54
US$4.00
+13.0%
25.0%US$5.00US$3.00n/a2
Mar ’25US$2.99
US$4.00
+33.8%
25.0%US$5.00US$3.00n/a2
Feb ’25US$2.44
US$3.75
+53.7%
33.3%US$5.00US$2.50n/a2
Sep ’24US$1.64
US$3.00
+82.9%
66.7%US$5.00US$1.00US$2.002
Aug ’24US$1.73
US$3.00
+73.4%
66.7%US$5.00US$1.00US$1.882
Jul ’24US$1.27
US$3.00
+136.2%
66.7%US$5.00US$1.00US$2.102
Jun ’24US$1.04
US$3.00
+188.5%
66.7%US$5.00US$1.00US$2.622
May ’24US$0.78
US$2.50
+219.6%
60.0%US$4.00US$1.00US$3.162
Apr ’24US$0.70
US$2.50
+259.7%
60.0%US$4.00US$1.00US$3.542
Mar ’24US$0.88
US$2.00
+128.0%
70.7%US$4.00US$1.00US$2.993
Feb ’24US$0.82
US$1.67
+103.4%
56.6%US$3.00US$1.00US$2.443
Jan ’24US$0.61
US$1.50
+145.8%
57.7%US$3.00US$1.00US$2.544
Dec ’23US$0.86
US$1.63
+88.4%
50.4%US$3.00US$1.00US$2.274
Nov ’23US$0.70
US$2.04
+192.7%
28.7%US$3.00US$1.50US$1.804

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

CVS Health

US$70.2b

Provides health solutions in the United States.

CVS

US$56.83

7D

4.7%

1Y

-17.8%

Centene

US$29.2b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$59.10

7D

1.8%

1Y

-20.4%

Elevance Health

US$91.4b

Operates as a health benefits company in the United States.

ELV

US$397.48

7D

-3.3%

1Y

-17.2%